A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist "Rescue" Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Salbutamol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 16 Mar 2020 Results published on 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 16 Mar 2020 Results published on 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 22 Mar 2018 Status changed from active, no longer recruiting to completed.